α-MSH and the stable analog NDP-MSH have both proven to be effective in ameliorating clinical symptoms in an experimental animal model of MS by limiting inflammation and neurodegeneration, which was attributed to MC1R signaling (11). The gene discussed is MC1R; the disease is myeloid sarcoma.